AnPac Bio-Medical Science, a company with operations in the United States and China focused on early cancer screening and detection, has received the first payment from a Malaysian customer who had signed a $1.5 million purchase contract for AnPac Bio's Model AP9080 cancer detection devices.

The Model AP9080 cancer detection device is based on company's patented, novel multi-cancer testing technology named Cancer Differentiation Analysis Technology (CDA).

As the first major sale of the company's cancer detection device into the Southeast Asia region, this is truly a milestone for the company. It also signifies that the company has formally entered the global cancer detection equipment market, as well as confirmation of AnPac Bio's novel technology, reputation, and its capability to penetrate into the vast global market.      

Under the terms of the purchase contract, AnPac Bio will provide its Model AP9080 cancer detection device, maintenance services, consumables and equipment parts to the Malaysian customer. The company will continue to receive revenues from services, consumables and equipment parts after the equipment sale. The Malaysian customer plans to set up bio-medical labs, obtain Laboratory Developed Test (LDT) certification and carry out paid cancer tests.  

The Ccmpany's CDA cancer detection technology is based on measuring biophysical properties in the blood. It has several major advantages over the traditional technologies, including its ability to detect multiple cancer types at early stage, while being cost effective, relatively simple to implement, and provides high sensitivity and specificity. According to a report by US marketing research firm Frost & Sullivan in 2021, AnPac Bio ranked number one in multi-cancer testing sample size in the world.